Lessons Learnt from Recent Trials in Ischemic Heart Disease

John M. Mandrola; Sanjay Kaul; Andrew Foy

doi:10.1055/s-0040-1715830

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2021; 121(01): 008-014
DOI: 10.1055/s-0040-1715830

Invited Clinical Focus

Lessons Learnt from Recent Trials in Ischemic Heart Disease

Autoren

John M. Mandrola

¹Department of Cardiology, Baptist Health Louisville, Louisville, Kentucky, United States
Sanjay Kaul

²Department of Cardiology, Cedars-Sinai Medical Center, Los Angeles, California, United States
Andrew Foy

³Department of Cardiology, Penn State College of Medicine, Hershey, Pennsylvania, United States

Abstract

Four recently published randomized controlled trials have informed the care of patients with stable ischemic heart disease. The purpose of this clinical focus article is to offer a summary and critical appraisal of the recent evidence. We aim to aid clinicians in the translation of the trial evidence to patient care.

Keywords

ischemic heart disease - percutaneous coronary intervention - coronary artery bypass graft - placebo

Volltext

Referenzen

References
1 Maron DJ, Hochman JS, O'Brien SM. et al; ISCHEMIA Trial Research Group. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: rationale and design. Am Heart J 2018; 201: 124-135
2 Frye RL, August P, Brooks MM. et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-2515
3 Boden WE, O'Rourke RA, Teo KK. et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356 (15) 1503-1516
4 Shaw LJ, Weintraub WS, Maron DJ. et al. Baseline stress myocardial perfusion imaging results and outcomes in patients with stable ischemic heart disease randomized to optimal medical therapy with or without percutaneous coronary intervention. Am Heart J 2012; 164 (02) 243-250
5 Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107 (23) 2900-2907
6 Murthy VL, Eagle KA. ISCHEMIA: a search for clarity and why we may not find it. Am Heart J 2018; 203: 82-84
7 Maron DJ, Hochman JS, Reynolds HR. et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med 2020; 382: 1395-1407
8 Spertus JA, Jones PG, Maron DJ. et al. Health-status outcomes with invasive or conservative care in coronary disease. N Engl J Med 2020; 382: 1408-1419
9 Bangalore S, Maron DJ, O'Brien SM. et al. Management of coronary disease in patients with advanced kidney disease. N Engl J Med 2020; 382: 1608-1618
10 Mancini GBJ, Hartigan PM, Shaw LJ. et al. Predicting outcome in the COURAGE trial (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation): coronary anatomy versus ischemia. JACC Cardiovasc Interv 2014; 7 (02) 195-201
11 Rajkumar CA, Nijjer SS, Cole GD, Al-Lamee R, Francis DP. ‘Faith Healing’ and ‘Subtraction Anxiety’ in unblinded trials of procedures: lessons from DEFER and FAME-2 for end points in the ISCHEMIA trial. Circ Cardiovasc Qual Outcomes 2018; 11 (03) e004665
12 Al-Lamee R, Thompson D, Dehbi H-M. et al; ORBITA investigators. Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial. Lancet 2018; 391 (10115): 31-40
13 Chaitman BR, Skettino SL, Parker JO. et al; MARISA Investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004; 43 (08) 1375-1382
14 Borer JS, Fox K, Jaillon P, Lerebours G. Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003; 107 (06) 817-823
15 Francis DP, Al-Lamee R. Percutaneous coronary intervention for stable angina in ORBITA - authors' reply. Lancet 2018; 392 (10141): 28-30
16 Al-Lamee R, Howard JP, Shun-Shin MJ. et al. Fractional flow reserve and instantaneous wave-free ratio as predictors of the placebo-controlled response to percutaneous coronary intervention in stable single-vessel coronary artery disease. Circulation 2018; 138 (17) 1780-1792
17 Al-Lamee RK, Shun-Shin MJ, Howard JP. et al. Dobutamine stress echocardiography ischemia as a predictor of the placebo-controlled efficacy of percutaneous coronary intervention in stable coronary artery disease: the stress echocardiography-stratified analysis of ORBITA. Circulation 2019; 140 (24) 1971-1980
18 A Placebo-controlled Trial of Percutaneous Coronary Intervention for the Relief of Stable Angina - Full Text View - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03742050 . Accessed August 10, 2020
19 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients with Stable Ischemic Heart Disease | Circulation 2012;126:e354–e471
20 Stone GW, Sabik JF, Serruys PW. et al; EXCEL Trial Investigators. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med 2016; 375 (23) 2223-2235
21 Stone GW, Kappetein AP, Sabik JF. et al; EXCEL Trial Investigators. Five-year outcomes after PCI or CABG for left main coronary disease. N Engl J Med 2019; 381 (19) 1820-1830
22 Holm NR, Mäkikallio T, Lindsay MM. et al; NOBLE investigators. Percutaneous coronary angioplasty versus coronary artery bypass grafting in the treatment of unprotected left main stenosis: updated 5-year outcomes from the randomised, non-inferiority NOBLE trial. Lancet 2020; 395 (10219): 191-199
23 Moussa ID, Klein LW, Shah B. et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol 2013; 62 (17) 1563-1570
24 Ruel M, Falk V, Farkouh ME. et al. Myocardial revascularization trials. Circulation 2018; 138 (25) 2943-2951
25 Cho MS, Ahn J-M, Lee C-H. et al. Differential rates and clinical significance of periprocedural myocardial infarction after stenting or bypass surgery for multivessel coronary disease according to various definitions. JACC Cardiovasc Interv 2017; 10 (15) 1498-1507
26 Serruys PW, Morice M-C, Kappetein AP. et al; SYNTAX Investigators. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360 (10) 961-972
27 Brown DC, Brown E. Surgeons withdraw support for heart disease advice. BBC News 2019
28 Khan MS, Ochani RK, Shaikh A. et al. Fragility index in cardiovascular randomized controlled trials. Circ Cardiovasc Qual Outcomes 2019; 12: e005755
29 Should Percutaneous Coronary Intervention Be Considered for Left Main Coronary Artery Disease? Insights From a Bayesian Reanalysis of the EXCEL Trial | Cardiology | JAMA Internal Medicine | JAMA Network 2020;180(7):1002–1003
30 EXCEL Leaders Answer Back After BBC Exposé. Medscape
31 EACTSJM A. EACTS responds to BBC Newsnight's investigation on the EXCEL trial. EACTS 2019
32 Cohen D, Brown E. New England Journal of Medicine reviews controversial stent study. BMJ British Medical Journal Publishing Group; 2020: 368
33 Baumgartner H, Falk V, Bax JJ. et al; ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 2017; 38 (36) 2739-2791
34 Stacey D, Légaré F, Col NF. et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014; (01) CD001431